New triple-drug attack shows promise for hard-to-treat ovarian cancer
NCT ID NCT07286240
First seen Jan 05, 2026 · Last updated May 23, 2026 · Updated 19 times
Summary
This study tests a new combination of drugs for people whose ovarian cancer has returned after standard treatment. The drugs include QL1706 (a dual-target immunotherapy), chemotherapy, and anlotinib (a pill that blocks blood vessel growth to tumors). About 40 participants will receive this combo to see if it shrinks tumors and delays cancer growth. The goal is to find a more effective option for recurrent ovarian cancer, which is often hard to treat.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TREATMENT OF RECURRENT OVARIAN CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Lipai Chen
RECRUITINGGuangzhou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.